1. A nuclear chocolate box: the periodic table of nuclear medicine
   Philip J. Blower, 2015, Dalton Transactions CrossRef
2. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
   null Vorobyeva et al, 2019, International Journal of Molecular Sciences CrossRef
3. In vitro modeling of HER2-targeting therapy in disseminated prostate cancer
   JENNIE ANDERSSON et al, 2014, International Journal of Oncology CrossRef
4. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
   Anzhelika Vorobyeva et al, 2018, Scientific Reports CrossRef
5. In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors
   Mohamed Altai et al, 2013, Cancer Biotherapy and Radiopharmaceuticals CrossRef
6. Gram-Scale Antibody–Drug Conjugate Synthesis by Site-Specific Chemical Conjugation: AJICAP First Generation
   Yutaka Matsuda et al, 2019, Organic Process Research & Development CrossRef
7. Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
   Vladimir Tolmachev et al, 2012, Journal of Nuclear Medicine CrossRef
8. Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26
   Bogdan Mitran et al, 2019, International Journal of Cancer CrossRef
9. Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients
   JENNIE ANDERSSON et al, 2015, Oncology Letters CrossRef
10. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts
    Jennie Malmberg et al, 2012, European Journal of Nuclear Medicine and Molecular Imaging CrossRef
11. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga
    Sarah Lindbo et al, 2018, Molecular Pharmaceutics CrossRef
12. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model
    Yun Jung Bae et al, 2016, Korean Journal of Radiology CrossRef
13. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
    Anzhelika Vorobyeva et al, 2018, Contrast Media & Molecular Imaging CrossRef
14. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
    Sergey Deyev et al, 2019, Molecular Pharmaceutics CrossRef
15. Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with 68Ga and 111In via Maleimido Derivatives of DOTA and NODAGA
    Mohamed Altai et al, 2013, Bioconjugate Chemistry CrossRef
16. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody
    Jennie Malmberg et al, 2011, Nuclear Medicine and Biology CrossRef
17. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA
    Mohamed Altai et al, 2012, Nuclear Medicine and Biology CrossRef
18. Matching chelators to radiometals for radiopharmaceuticals
    Eric W. Price et al, 2014, Chem. Soc. Rev. CrossRef
19. ImmunoPET for prostate cancer in the PSMA era: do we need other targets?
    Luca Filippi et al, 2022, Clinical and Translational Imaging CrossRef